by Eric Christianson | Feb 12, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influenceclinical practice. In this video, I discuss the combined usage of antiplatelets with DOACsin patients with ASCVD risk and atrial fibrillation. Each mechanism of action is reviewed,as...
by Eric Christianson | Feb 9, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influence clinical practice. In this video, I discuss whether beta-blocker use post-MI is beneficial for patients with HFpEF. Background about the mechanism of action and typical place in...
by Eric Christianson | Feb 5, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influence clinical practice. Finerenone has been studied in the setting of HFpEF and I review this topic. More specifically, in this video, I discuss the background of why finerenone may be...
by Eric Christianson | Jan 29, 2025 | Drug Interaction Case Studies and Education For Pharmacists
Statins are one of the most commonly prescribed medications to help manage hyperlipidemia and reduce the risk of cardiovascular events. However, statins are notorious for their drug interactions which can pose a significant risk to patients if not taken into...
by Eric Christianson | Jan 26, 2025 | Endocrine Medication and Disease State Clinical Pearls
Type II diabetes is a complicated disease state that often requires a combination of medications to control. However, some combinations of antidiabetes medications, such as sulfonylureas and basal insulin, may lead to unintended adverse effects. In this article, we...
